The University of Oxford reported on Tuesday that it stopped testing its vaccine – developed with AstraZeneca – in children and adolescents. The measure will be maintained until the “Medicines and Healthcare products Regulatory Agency” (MHRA) provides more information on a possible link with blood clots.
According to a statement received by EFE news agency, a spokesperson for the University said that there are no safety concerns in the pediatric clinical trial, but that the institution has decided to “wait for additional information from the MHRA on its investigation of rare cases of thrombosis before administering more vaccines”.
The announcement does not mean the end of the trials but that they will wait for the regulatory body’s conclusions. The situation comes at a time when more than 31 million Britons have already received their first dose.
Vaccination with AstraZeneca continues
The British government continues to ask its citizens to go to vaccination centers to receive the injection of some of the two licensed vaccines, which are the Oxford and the Pfizer vaccine.
So far, seven people have died in the United Kingdom as a result of blood clots after receiving the AstraZeneca vaccine. For its part, the World Health Organization (WHO), through a statement in mid-March, considered that: “The benefits of the AstraZeneca vaccine outweigh its risks and [WHO] recommends that the vaccine should continue to be administered”.